A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL

References

• Bassan R, Maino E, Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol. 2016;96(5):447–460. doi:10.1111/ejh.12722
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Eroglu C, Pala C, Kaynar L, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leukemia Lymphoma. 2013;54:2474–2479. doi:10.3109/10428194.2013.779691
   PubMed Web of Science ®Google Scholar
• Abaza YM, Kantarjian H, Faderl S, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93:91–99. doi:10.1002/ajh.24947
   PubMed Web of Science ®Google Scholar
• Samra B, Alotaibi AS, Short NJ, et al. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020;95(9):E245–E247. doi:10.1002/ajh.25896
   PubMed Web of Science ®Google Scholar
• Baek DW, Lee JM, Kim J, et al. Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. Expert Rev Hematol. 2021;14:765–775. doi:10.1080/17474086.2021.1960817
   PubMed Web of Science ®Google Scholar
• Yasuda S, Najima Y, Konishi T, et al. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leukemia RES. 2021;108:106627. doi:10.1016/j.leukres.2021.106627
   PubMed Web of Science ®Google Scholar
• Hu M, Wang H, Wang L, Yang M, Lou Y, Jin J. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore). 2018;97:e11374. doi:10.1097/MD.0000000000011374
   PubMed Web of Science ®Google Scholar
• Famoso JM, Grow JL, Laughlin B, et al. The impact of Low-dose cranial boost on the long-term outcomes of adult patients with high-risk acute lymphoblastic leukemia undergoing total body irradiation and allogeneic hematopoietic stem cell transplantation. Pract Radiat Oncol. 2019;9:e283–e289. doi:10.1016/j.prro.2018.12.005
   PubMed Web of Science ®Google Scholar
• Cahu X, Labopin M, Giebel S, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transpl. 2016;51:351–357. doi:10.1038/bmt.2015.278
   PubMed Web of Science ®Google Scholar
• Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. doi:10.1186/s13045-017-0439-6
   PubMedGoogle Scholar
• Guan W, Jing Y, Dou L, et al. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia. Leukemia Lymphoma. 2020;61:855–861. doi:10.1080/10428194.2019.1691195
   PubMed Web of Science ®Google Scholar
• Xi M, Guo S, Bayin C, et al. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia. Front Med. 2022;16:442–458. doi:10.1007/s11684-021-0877-y
   PubMed Web of Science ®Google Scholar
• Haferlach T, Kern W, Schnittger S, et al. Modern diagnostics in acute leukemias. Crit Rev Oncol Hemat. 2005;56:223–234. doi:10.1016/j.critrevonc.2004.04.008
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46:64–75. doi:10.1053/j.seminhematol.2008.09.003
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-1833.
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:1079–1109. doi:10.6004/jnccn.2021.0042
   PubMed Web of Science ®Google Scholar
• Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401–1415. doi:10.1038/s41409-018-0204-7
   PubMed Web of Science ®Google Scholar
• Pavlu J, Labopin M, Niittyvuopio R, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12:108. doi:10.1186/s13045-019-0790-x
   PubMed Web of Science ®Google Scholar
• Hamilton BK, Rybicki L, Abounader D, et al. Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2017;23:1117–1121. doi:10.1016/j.bbmt.2017.04.003
   PubMed Web of Science ®Google Scholar
• Wong J, Filippi AR, Scorsetti M, et al. Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. Lancet Oncol. 2020;21:e477–e487. doi:10.1016/S1470-2045(20)30342-9
   PubMed Web of Science ®Google Scholar
• Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16:494–507. doi:10.1038/nrc.2016.63
   PubMed Web of Science ®Google Scholar
• Cordo’ V, van der Zwet J, Cante-Barrett K, Pieters R, Meijerink J. T-cell acute lymphoblastic leukemia: A roadmap to targeted therapies. Blood Cancer Discov. 2021;2:19-31. doi:10.1158/2643-3230.BCD-20-0093
   PubMedGoogle Scholar
• Zhao A, Zhou H, Yang J, et al. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct Target Ther. 2023;8:71. doi:10.1038/s41392-023-01342-6
   PubMed Web of Science ®Google Scholar
• Cheung LC, Cruickshank MN, Hughes AM, et al. Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. Haematologica. 2019;104:e300–e303. doi:10.3324/haematol.2018.192906
   PubMed Web of Science ®Google Scholar
• Choi S, Reddy P. HDAC inhibition and graft versus host disease. Mol Med. 2011;17:404–416. doi:10.2119/molmed.2011.00007
   PubMed Web of Science ®Google Scholar
• Sanchez-Martin M, Ferrando A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood. 2017;129:1124–1133. doi:10.1182/blood-2016-09-692582
   PubMed Web of Science ®Google Scholar
• Chi Z, Gao H, Liu H, et al. Chidamide induces necroptosis via regulation of c-FLIPL expression in Jurkat and HUT-78 cells. Mol Med Rep. 2020;21:936–944.
   PubMed Web of Science ®Google Scholar
• Chen F, Pang D, Guo H, et al. Clinicopathological characteristics and mutational profiling of adult T-cell lymphoblastic lymphoma in a Chinese population. Cancer Manag Res. 2020;12:3003–3012. doi:10.2147/CMAR.S242903
   PubMed Web of Science ®Google Scholar
• Li X, Han X, Huang K, et al. Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study. Front Med-Lausanne. 2023;10.
   Web of Science ®Google Scholar